CCR4

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Retrieved on: 
Tuesday, April 9, 2024
CPI, CPS, Disease, HNSCC, Patient, SAN, Inflammation, Pembrolizumab, HPV, AACR, CCR4, Therapy, PD-L1, Safety, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) --  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced safety and efficacy data from its ongoing Phase 2 trial of tivumecirnon in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab in the cohort of patients with advanced head and neck squamous cell carcinoma (HNSCC) whose disease progressed despite previous treatment with CPI therapy (CPI-experienced). The results were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

Key Points: 
  • The results were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
  • The AACR poster highlighted data from the 32-patient CPI-experienced HNSCC cohort in the trial evaluating tivumecirnon, an oral small molecule CCR4 antagonist designed to block the migration of regulatory T cells, in combination with pembrolizumab.
  • Patients in this cohort had heavily pretreated disease, with 69% of patients having received three or more (up to six) prior lines of treatment.
  • In the entire cohort, confirmed responses were observed in 5/32 patients (15.6%) regardless of PD-L1 or HPV status.

Innovaderm, a Key Collaborator in Clinical and Study Development for Recently Published Phase 1 Atopic Dermatitis Study

Retrieved on: 
Tuesday, December 19, 2023
Health, Other Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Clinical trial, Pharmacokinetics, Patient, Safety, Skin, CCR4, Biotechnology, RAPT, Pharmaceutical industry

Allergy recently published RAPT Therapeutics’ phase 1a/1b atopic dermatitis (AD) study, in which Innovaderm Research was a key partner, serving as the contract research organization (CRO).

Key Points: 
  • Allergy recently published RAPT Therapeutics’ phase 1a/1b atopic dermatitis (AD) study, in which Innovaderm Research was a key partner, serving as the contract research organization (CRO).
  • Innovaderm has distinguished itself through specific factors which were significant in the successful conduct of the clinical trial.
  • The study design involved a single ascending dose / multiple ascending dose (SAD/MAD) portion in healthy volunteer subjects, followed by a cohort of 31 AD participants.
  • Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials.

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

Retrieved on: 
Friday, November 3, 2023
Therapy, PD-L1, NSCLC, PD, Johns Hopkins University, Society for Immunotherapy of Cancer, Pembrolizumab, PFS, Inflammation, Poster, SITC, Immunotherapy, RAPT, Annual general meeting, ORR, Lung cancer, Safety, Society, Patient, CCR4, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced safety and efficacy data from its Phase 2 trial of FLX475 (tivumecirnon) in patients with advanced non-small cell lung cancer (NSCLC) who had no prior checkpoint inhibitor therapy. The trial evaluated FLX475, an oral small molecule CCR4 antagonist designed to block the migration of regulatory T cells, in combination with the checkpoint inhibitor pembrolizumab. In this cohort of NSCLC patients, 36 patients were evaluable for efficacy, of which 20 were PD-L1 positive. In these PD-L1 positive patients, the combination of FLX475 and pembrolizumab showed a 40% (8/20) confirmed ORR and a median PFS of 6.3 months as of the data cut off date, with seven patients continuing on study. For comparison, historical pembrolizumab monotherapy activity in checkpoint inhibitor-naïve and previously-treated NSCLC patients showed a confirmed ORR of 18% and a median PFS of 4.0 months. The confirmed ORR for the combination of FLX475 and pembrolizumab in PD-L1 low and high subsets were 38% (6/16) and 50% (2/4), respectively. For comparison, the ORR for pembrolizumab monotherapy in the PD-L1 low and high subsets has been previously reported as 10% and 30%, respectively.

Key Points: 
  • The trial evaluated FLX475, an oral small molecule CCR4 antagonist designed to block the migration of regulatory T cells, in combination with the checkpoint inhibitor pembrolizumab.
  • In this cohort of NSCLC patients, 36 patients were evaluable for efficacy, of which 20 were PD-L1 positive.
  • The confirmed ORR for the combination of FLX475 and pembrolizumab in PD-L1 low and high subsets were 38% (6/16) and 50% (2/4), respectively.
  • “We are excited by the response rates and PFS data for FLX475 in combination with a checkpoint inhibitor in this cohort of NSCLC patients.

Nutcracker Therapeutics to Present Data for Two mRNA Drug Candidates at SITC 2023

Retrieved on: 
Tuesday, October 24, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Cancer, RNA, Nutcracker, HPV, EST, CD47, Immunotherapy, Conference, Journal, SITC, JITC, Neoplasm, IL-12, Abstract, Messenger, Society, Therapy, CCR4, Vaccine

These data will be presented at the Society for Immunotherapy of Cancer’s (SITC’s) 38th Annual Meeting & Pre-Conference Programs (SITC 2023) in San Diego, CA, from November 1 through 5, 2023.

Key Points: 
  • These data will be presented at the Society for Immunotherapy of Cancer’s (SITC’s) 38th Annual Meeting & Pre-Conference Programs (SITC 2023) in San Diego, CA, from November 1 through 5, 2023.
  • Title: mNTX-250, a novel multimodal HPV-16 mRNA-based therapeutic, induces potent anti-tumor responses and establishes HPV-16 specific immune memory
    Poster presentations will be accessible in person and virtually.
  • All accepted abstracts will be available in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on October 31 at 9:00 a.m. EST.
  • For more information about SITC 2023, please visit https://www.sitcancer.org/home .

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Retrieved on: 
Monday, August 14, 2023
Monoclonal antibody, Growth factor, CD3, Neoplasm, CCR4, Head, Breast, CCR8, Antibody, Doctor of Philosophy, Lung, Animal, Cancer, SAN, EGFR, Carcinoma, IND, Vaccine, Pharmaceutical industry

BRYAN, Texas and SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced positive pre-clinical in vivo data for three immuno-oncology candidates, anti-EGFRvIII, CCR8 and a bispecific TROP-2 x CD3, advancing these programs to clinical candidate selection stage.

Key Points: 
  • In preclinical studies, iBio’s anti-EGFRvIII antibody demonstrated a 43 percent reduction in tumor growth compared to untreated animals.
  • iBio developed the antibody using its patented AI epitope steering technology.
  • By focusing solely on the tumor-specific variant, iBio aims to reduce potential side effects.
  • In addition to the anti-EGFR program, iBio’s CCR8 antibody has proven effective in a mouse model for colon cancer.

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

Retrieved on: 
Thursday, May 25, 2023
Tissue, Therapy, Epstein–Barr virus, Neoplasm, Clinical trial, CCR4, NSCLC, RAPT, Lung cancer, ASCO, American Society of Clinical Oncology, Patient, SAN, TME, Poster, Pembrolizumab, Tumor microenvironment, PD-L1, Society, Inflammation, Protocol, Pharmaceutical industry, Regulatory T cell

SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced biomarker data for FLX475 from its ongoing FLX475-02 Phase 1/2 clinical trial which corroborate the clinical activity of FLX475 reported in Epstein-Barr virus-positive (EBV+) lymphoma, EBV+ gastric cancer and non-small cell lung cancer (NSCLC), as well as the mechanism of this novel CCR4 antagonist. These data will be presented in a poster at the 2023 American Society of Clinical Oncology (ASCO) annual meeting taking place next week at the McCormick Place Convention Center in Chicago, IL.

Key Points: 
  • In December 2022 at ESMO-IO, a clinical update from the Phase 1/2 trial reported evidence of monotherapy and combination activity.
  • FLX475 monotherapy induced confirmed complete metabolic responses in two of the six evaluable patients with EBV+ NK/T cell lymphoma.
  • These data substantiate the mechanism of action and support the combination of FLX475 with pembrolizumab.
  • These data are consistent with and support the clinical activity we’ve seen with FLX475 as monotherapy and in combination therapy with pembrolizumab.”

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Retrieved on: 
Friday, March 31, 2023
Interim, Therapy, G protein-coupled receptor, Half-life, CCR4, CCR8, Doctor of Philosophy, Regulatory T cell, GPCR, Immune system, IL2, Immunosuppression, DVM, Tumor microenvironment, Vaccine

BRYAN, Texas, March 31, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the progression of its anti-CCR8 antibody immuno-oncology program into preclinical in vivo testing. CCR8, a member of the G protein-coupled receptor (“GPCR”) family, is expressed by T-regulatory cells (“Tregs”) that play a crucial role in inducing immunosuppression across various cancer types.

Key Points: 
  • BRYAN, Texas, March 31, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the progression of its anti-CCR8 antibody immuno-oncology program into preclinical in vivo testing.
  • iBio employed its patented AI epitope steering platform in the discovery of anti-CCR8 molecules to overcome certain challenges associated with developing antibody-based GPCR-targeting therapeutics.
  • We are pleased to be able to now move our anti-CCR8 molecules into in vivo testing."
  • Dillon Phan, PhD, iBio’s VP and Head of Early Research & Development, added, “We are thrilled to expand our Treg depletion franchise through our new anti-CCR8 program, which complements our existing IBIO-101 program.

RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress

Retrieved on: 
Thursday, December 1, 2022
Inflammation, RAPT, CCR4, Therapy, Patient, Security (finance), Cancer, Risk, Pharmaceutical industry

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology.

Key Points: 
  • RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology.
  • Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases.
  • RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively.
  • RAPT disclaims any obligation to update these forward-looking statements, except as required by law.

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Friday, November 18, 2022
Cantor, SAN, Inflammation, Attention, Madison Avenue, Telephone, RAPT, Floor, Therapy, CCR4, Patient, Prospectus, Equity capital markets, Capital market, The Women on the 6th Floor, Sale, Guggenheim Partners, Cancer, Park Avenue, Broadridge Financial Solutions, Pharmaceutical industry, Security (finance)

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc.(Nasdaq: RAPT) (RAPT or the Company), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the pricing of its previously announced underwritten public offering of 4,054,055 shares of its common stock at a price to the public of$18.50 per share.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc.(Nasdaq: RAPT) (RAPT or the Company), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the pricing of its previously announced underwritten public offering of 4,054,055 shares of its common stock at a price to the public of$18.50 per share.
  • All of the shares of common stock are being offered by RAPT.
  • Gross proceeds to RAPT from the offering are expected to be $75 million, before deducting underwriting discounts and commissions and estimated offering expenses.
  • In addition, the underwriters have been granted a 30-day option to purchase up to an additional 608,108 shares of common stock at the public offering price, less underwriting discounts and commissions.

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Thursday, November 17, 2022
Cantor, SAN, Inflammation, Attention, Madison Avenue, Telephone, Risk, RAPT, Floor, Therapy, CCR4, Patient, Prospectus, Equity capital markets, Capital market, The Women on the 6th Floor, Guggenheim Partners, Cancer, Sale, Park Avenue, Pharmaceutical industry, Security (finance)

In addition, RAPT expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common stock on the same terms and conditions.

Key Points: 
  • In addition, RAPT expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common stock on the same terms and conditions.
  • All of the shares of common stock are being offered by RAPT.
  • The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.
  • J.P. Morgan, Evercore ISI, Guggenheim Securities and Cantor are acting as joint book-running managers for the proposed offering.